The global tissue diagnostics market reached a value of US$ 4 Billion in 2019. Tissue diagnostics include the analysis and testing of specific tissue samples by capturing the biological context of diseases. They are used to detect certain medical conditions like cancer and inflammatory disorders and reveal the exact type and degree of malignancy which assists in identifying potential causes and treatment options. Tissue diagnostics are highly accurate, inexpensive and can be carried out by different techniques like core and open biopsy. Nowadays, advanced technologies like immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology and special staining are also being employed for performing these diagnoses.
Owing to the declining fertility rates and increased life expectancy, the overall share of the geriatric population is currently experiencing steady growth worldwide. This is a crucial factor contributing to the market growth as older adults are more susceptible to chronic diseases and thus require frequent check-ups and diagnoses. Apart from this, altering food patterns, rising alcohol consumption and reduced physical activities among individuals have led to a rise in the incidences of several lifestyle diseases. In addition to this, the rising prevalence of various types of cancers among all age groups has also led to a surge in demand for these diagnostic services. Looking forward, IMARC Group expects the global tissue diagnostics market to exhibit moderate growth during the next five years.
The report has also analysed the competitive landscape of the market with some of the key players being Roche, Danaher, Thermo Fisher Scientific, Abbott, Agilent Technologies, Merck, Sakura Finetek Japan, Abcam, BD, Qiagen, Bio SB, Biogenex, Cell Signaling Technology, etc
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-702-409-7331 )
( India: +91-120-433-0800 )
Drop us an email at